Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Advances in IBD Precision Medicine With Therapeutic Drug Monitoring
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Released: February 16, 2022 Expiration: February 15, 2023
Start Activity
Provided by the American Gastroenterological Association, in collaboration with Clinical Care Options.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Pharmaceuticals U.S.A., Inc.
Marla Dubinsky, MD
Bruce E. Sands, MD, MS

Learning Objectives

Upon completion of this activity, participants should be able to:

Information on this Educational Activity

Faculty

Marla Dubinsky, MD

Chief of Pediatric Gastroenterology and Nutrition
Co-Director, 
Susan and Leonard Feinstein IBD Clinical Center
Icahn School of Medicine
Mount Sinai, New York

Marla C. Dubinsky, MD, has disclosed that she has received consulting fees from AbbVie, Arena, Bristol-Myers Squibb, Janssen, Lilly, Pfizer, Prometheus, and Trellus Health; funds for research support from AbbVie, Janssen, and Prometheus; and has ownership interest and intellectual property rights in Trellus Health.
Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology

Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Bruce E. Sands, MD, MS, AGAF, has disclosed that he has received consulting fees from 4D Pharma, Abivax, AbbVie, Alimentiv, Allergan, Amgen, Arena, AstraZeneca, Bacainn, Boehringer-Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Capella, Celgene, Celltrion, ClostraBio, Enthera, F.Hoffmann-La Roche, Ferring, Galapagos, Gilead, Glaxo SmithKline, GossamerBio, Immunic, Index, Innovation, Ironwood, Janssen, Kaleido, Kallyope, Lilly, MiroBio, Morphic, Oppilan, OSE, Otsuka, Palatin, Pfizer, Progenity, Prometheus, Protagonist, Q32 Bio, Redhill, Rheos, Salix, Seres, Shire, Sienna, Sun Pharma, Surrozen, Takeda, Target PharmaSolutions, Teva, Thelium, Theravance, TLL Pharma, USWM Enterprises, Ventyx, Viela Bio, Vivante, and Vivelix; funds for research support from Takeda, Pfizer, Theravance, and Janssen; and has ownership interest in Ventyx and Vivante.

Staff

Craig Borders
Vice President, Managing Scientific Director
Craig Borders has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Laurie Powers, RN
Laurie Powers, RN has no relevant conflicts of interest to report

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The AGA Institute designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the American Gastroenterological Association. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

$name

$name

$name

$name

$name

$name

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 16, 2022, through February 15, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Introduction and Presurvey
  • CME
  • CE

Loading...
In this engaging, interactive, on-demand webcast, expert faculty review the rationale and current best practices for therapeutic drug monitoring (TDM) in patients with IBD. The data-driven discussion includes proactive and reactive TDM approaches for both TNF inhibitors and non-TNF inhibitor biologics.
Marla Dubinsky, MD
Bruce E. Sands, MD, MS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Released: February 16, 2022 Expiration: February 15, 2023

This program is divided into several short segments that you can step through using the Video Chapters menu.
PreviousNext

Related Content

Experts review new treatment strategies in IBD and how to address health inequities in patients, from Clinical Care Options (CCO)

Anita Afzali, MD, MPH, MHCM, FACG, AGAF
Program Director
David Hudesman, MD, FACG, AGAF Millie D. Long, MD, MPH, FACG, AGAF
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Physician Assistants: maximum of 1.5 hours of AAPA Category 1 CME credits Released: June 24, 2022 Expired: June 23, 2023

Drs. Anita Afzali, Millie Long, David Hudesman on latest IBD treatments, therapeutic challenges, individualized care, health inequity from Clinical Care Options (CCO)

Anita Afzali, MD, MPH, MHCM, FACG, AGAF
Program Director
David Hudesman, MD, FACG, AGAF Millie D. Long, MD, MPH, FACG, AGAF
Released: May 20, 2022

On-demand webcast featuring an expert panel with insight on new data presented at ECCO 2022 for Crohn disease and ulcerative colitis from Clinical Care Options (CCO)

Uma Mahadevan, MD Bruce E. Sands, MD, MS Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: May 19, 2022 Expired: May 18, 2023

Clinical Care Options (CCO) presents expert commentary on new data in Crohn disease and ulcerative colitis from ECCO 2022

Bruce E. Sands, MD, MS Released: May 13, 2022

Video Chapters


Provided by the American Gastroenterological Association, in collaboration with Clinical Care Options.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Pharmaceuticals U.S.A., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings